SAN DIEGO, May 20, 2019 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces the commercial launch of Target Selector™ NGS
Lung Panel, the Company's multi-gene liquid biopsy panel
specifically developed for lung cancer. This product runs on Thermo
Fisher Scientific's Ion Torrent™ next generation sequencing (NGS)
platform. The Target Selector™ NGS Lung Panel will be marketed to
physicians and researchers, and can be used to detect and monitor
actionable biomarkers associated with lung cancer. The panel
combines Biocept's laboratory and commercial infrastructure, as
well as the Company's expertise in blood sample preservation and
DNA/RNA isolation with Thermo
Fisher's industry leading next generation sequencing panel
and informatics technology, branded as Oncomine™. This offering
will also further enrich the content supporting Biocept's
collaboration with artificial intelligence solutions provider
Prognos Health, Inc.
Lung cancer is the leading cause of cancer death for both men
and women in the United States,
with an estimated 155,870 deaths in 2017.1 The median
overall survival for patients with advanced non-small cell lung
cancer (NSCLC) is approximately one year, with the five-year
survival rate for metastatic lung cancer at 5%.2
However, 17–27% of NSCLC patients harbor molecular alterations that
can be treated with specific FDA-approved targeted therapies. In
order to realize the full potential of these targeted therapies,
oncologists require timely and accurate molecular characterization
of a patient's cancer for selection of the best possible therapy,
with some treatment regimens extending median patient survival
times from one to two and one-half years.3-7 Despite
these advances, a large percentage of patients may not undergo
molecular profiling due to a number of practical constraints. Chief
among these is the availability of tissue for molecular testing.
Lung cancers are often difficult to biopsy because of their
location within what is often diseased lung tissue of elderly
patients. Biocept believes that the clinical utility of liquid
biopsy, which involves the use of a simple blood sample to obtain
this molecular information, can provide an effective solution to
help oncologists with the selection of targeted therapies.
"We are very pleased to launch our first multi-gene liquid
biopsy panel to physicians and researchers in both academic centers
and the pharmaceutical industry," said Michael Nall, Biocept's President and Chief
Executive Officer. "This new solution makes Biocept the only
commercial liquid biopsy company that can offer customers the
flexibility to order either a customized single biomarker assay or
a larger NGS-based liquid biopsy test panel for use when more
comprehensive testing is desired. This new offering complements our
existing Target Selector™ testing platform, which focuses on
delivering actionable and cost-effective biomarker information to
address needs of physicians, healthcare systems and payors as they
develop personalized treatment protocols for patients diagnosed
About Biocept's Target Selector™ NGS Lung
Biocept's multi-gene tumor-specific NGS-based liquid biopsy
panels allow physicians and researchers to use a simple blood
sample to analyze actionable biomarkers associated with specific
solid tumor types. The biomarkers included in the Target Selector™
NGS Lung Panel are those that physicians frequently rely upon when
making treatment decisions for their patients diagnosed with cancer
and includes reporting powered by the Oncomine™ Knowledge Reporter.
For more information about the Target Selector™ NGS Lung Panel,
please contact Biocept Customer Services at 888-332-7729.
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with information for
treating and monitoring patients diagnosed with cancer. The
Company's patented Target Selector™ liquid biopsy technology
platform captures and analyzes tumor-associated molecular markers
in both CTCs and in plasma (ctDNA). With thousands of tests
performed, the platform has demonstrated the ability to identify
cancer mutations and alterations to inform physicians about a
patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
outcomes of patients diagnosed with cancer, the potential clinical
utility of our proprietary technology platform and the
commercial success of our Target Selector™ NGS Lung Panel, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www/sec/gov.
Siegel RL, Miller KD,
Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017
Kim TE, Murren JR.
Therapy for stage IIIB and stage IV non-small cell lung cancer.
Clin Chest Med. 2002 Mar; 23(1):209-224.
Sequist LV, et al.
Phase III study of afatinib or cisplatin plus pemetrexed in
patients with metastatic lung adenocarcinoma with EGFR mutations.
J Clin Oncol. 2013 Sep 20; 31(27):3327-3334.
Fukuoka M, et al.
Biomarker analyses and final overall survival results from a phase
III, randomized, open-label, first-line study of gefitinib versus
carboplatin/paclitaxel in clinically selected patients with
advanced non-small-cell lung cancer in Asia (IPASS). J Clin
Oncol. 2011 Jul 20; 29(21):2866-2874.
Rosell R, et al.
Erlotinib versus standard chemotherapy as first-line treatment for
European patients with advanced EGFR mutation-positive
non-small-cell lung cancer (EURTAC): a multicentre, open-label,
randomised phase 3 trial. Lancet Oncol. 2012 Mar;
Maemondo M, et al.
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 2010 Jun 24;
Chih-Hsin Yang J et
al Afatinib versus cisplatin based chemotherapy for EGFR mutation
positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis
of overall survival from two randomized phase 3 trials Lancet
Oncology 2015;16 141-151
LHA Investor Relations
View original content to download
SOURCE Biocept, Inc.